By Nicole Narea ( January 18, 2018, 9:11 PM EST) -- Allergan Inc.'s request to leave a series of patent challenges tied to its dry-eye medication Restasis should be rejected because the company's deal to transfer the patents to a Native American tribe does not shield the firm from liability, a generic-drug maker told the Patent Trial and Appeal Board Wednesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.